Nomura Holdings
PCRX icon

Nomura Holdings’s Pacira BioSciences PCRX Stock Holding History

Nomura Holdings’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-18,502
Closed -$477K – 2098
2025
Q3 		$477K Sell
18,502
-100,407
-84% -$2.47M ﹤0.01% 1612
2025
Q2 		$2.84M Buy
+118,909
New +$3M 0.01% 738
2024
Q4 		– Sell
-89,998
Closed -$1.58M – 2340
2024
Q3 		$1.35M Sell
89,998
-14,758
-14% -$252K ﹤0.01% 1063
2024
Q2 		$3M Buy
104,756
+95,283
+1,006% +$2.71M 0.01% 822
2024
Q1 		$277K Sell
9,473
-15,786
-62% -$485K ﹤0.01% 1381
2023
Q4 		$852K Buy
+25,259
New +$739K ﹤0.01% 1226
2023
Q1 		– Sell
-6,434
Closed -$248K – 1661
2022
Q4 		$248K Buy
+6,434
New +$313K ﹤0.01% 1081
2022
Q1 		– Sell
-848
Closed -$51K – 2310
2021
Q4 		$51K Sell
848
-4,157
-83% -$229K ﹤0.01% 2062
2021
Q3 		$285K Sell
5,005
-9,413
-65% -$543K ﹤0.01% 1576
2021
Q2 		$876K Sell
14,418
-34,581
-71% -$2.19M ﹤0.01% 1122
2021
Q1 		$3.44M Buy
48,999
+44,214
+924% +$3.16M 0.01% 678
2020
Q4 		$286K Sell
4,785
-7,215
-60% -$422K ﹤0.01% 1337
2020
Q3 		$721K Buy
+12,000
New +$697K ﹤0.01% 903
2020
Q2 		– Sell
-6,095
Closed -$204K – 1233
2020
Q1 		$204K Sell
6,095
-16,247
-73% -$675K ﹤0.01% 755
2019
Q4 		$1.01M Sell
22,342
-433
-2% -$18.4K ﹤0.01% 795
2019
Q3 		$840K Sell
22,775
-23,755
-51% -$948K ﹤0.01% 882
2019
Q2 		$1.98M Buy
46,530
+119
+0.3% +$5.05K 0.01% 688
2019
Q1 		$1.74M Buy
46,411
+12,838
+38% +$501K 0.01% 689
2018
Q4 		$1.44M Buy
33,573
+23,573
+236% +$1.1M 0.01% 779
2018
Q3 		$478K Buy
+10,000
New +$432K ﹤0.01% 1010
2014
Q4 		– Sell
-3,096
Closed -$295K – 2607
2014
Q3 		$295K Buy
3,096
+208
+7% +$20.2K ﹤0.01% 2185
2014
Q2 		$259K Sell
2,888
-1,531
-35% -$117K ﹤0.01% 2226
2014
Q1 		$313K Buy
+4,419
New +$301K ﹤0.01% 2060

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Nomura Holdings's PCRX Position: Q4 2025 in Review

Nomura Holdings sold out of Pacira BioSciences (PCRX) in Q4 2025, closing a stake of 18,502 shares — an estimated $477K sold.

Nomura Holdings first reported a position in PCRX in Q1 2014 and held it in 23 quarters. The position peaked at $3.44M in Q1 2021. 260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

  • Nomura Holdings reported no remaining Pacira BioSciences position as of Q4 2025 after selling out during the quarter.
  • Nomura Holdings sold 18,502 Pacira BioSciences shares in Q4 2025, an estimated $477K.
  • Nomura Holdings first reported a position in Pacira BioSciences in Q1 2014 and held it in 23 quarters.
  • Nomura Holdings's Pacira BioSciences position peaked at $3.44M in Q1 2021.
  • 260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Nomura Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.